Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Registration Number
- NCT00813098
- Lead Sponsor
- Lexicon Pharmaceuticals
- Brief Summary
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 155
- Males and females aged 18-70 years old
- Documented diagnosis of IBS (IBS-diarrhea or IBS-mixed) based upon Rome III criteria
- Abdominal pain/discomfort at least 2 days per week during the screening and run-in periods
- Normal structural evaluation of the colon within 5 years prior to screening
- Ability to provide written informed consent
- Inability to discontinue current drug therapy for IBS, except for bulking agents, through the duration of the study
- Use of anticholinergic antidepressants, opioid pain medications, or any drugs that affect bowel motility
- Lactose intolerance
- Major psychological disorder
- Significant nicotine or caffeine use (>10 cigarettes and/or six 8 ounce cups of coffee per day, respectively)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description High dose LX1031 High Dose A high dose of LX1031; daily oral intake for 28 days Low Dose LX1031 Low Dose A low dose of LX1031; daily oral intake for 28 days Placebo Placebo Matching placebo dosing with daily oral intake
- Primary Outcome Measures
Name Time Method Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4 Week 4 The primary efficacy endpoint was the proportion of subjects experiencing relief of IBS pain and discomfort at Week 4 as measured by the response to the question,"In the past 7 days have you had adequate relief of your irritable bowel syndrome pain and discomfort?"
- Secondary Outcome Measures
Name Time Method Change From Baseline at Week 4 in Stool Frequency Baseline to Week 4 Subjects recorded the number of times they passed stool on a daily basis in the daily diary. The mean for Week 4 was subtracted from the baseline mean to obtain the mean change from baseline in stool frequency.
Change From Baseline at Week 4 in Proportion of Days Per Week When Experiencing Urgency to Defecate Baseline to Week 4 To assess sensation of urgency to defecate on a daily basis, subjects recorded in their daily diary a response to the following question,"Have you felt or experienced a sense of urgency to pass stool today?" The mean score (proportion of days per week when the subject experienced an urge to defecate) for Week 4 was subtracted from the baseline mean score to determine the mean change from baseline.
Change From Baseline at Week 4 in Stool Consistency Scores Baseline to Week 4 Stool consistency was evaluated using the 7-point Bristol Stool Scale in which a score of 1 indicates separate hard lumps, 2 indicates sausage shaped but lumpy, 3 indicates sausage-like with cracks on the surface, 4 indicates sausage-like but smooth and soft, 5 indicates soft blobs with clear cut edges, 6 indicates fluffy pieces with ragged edges, and 7 indicates watery with no solid pieces. The mean score for Week 4 was subtracted from the baseline mean score to obtain the mean change from baseline.
Change From Baseline at Week 4 on the Severity of Bloating Baseline to Week 4 Subjects recorded in the daily diary the level of bloating they felt on a daily basis using a 100 mm visual analog scale (with 0 being "not at all" and 100 mm being "worst possible"). The mean score for Week 4 was subtracted from the baseline mean score to obtain the mean change from baseline in severity of bloating.
Change From Baseline at Week 4 on the Global Improvement Score. Baseline to Week 4 The IBS Global Improvement Scale (IBS-GAI) asks "Compared to the way you felt before you entered the study, have your IBS symptoms over the past 7 days been: 1-substantially worse, 2-moderately worse, 3-slightly worse, 4-no change, 5-slightly improved, 6-moderately improved, 7-substantially improved?" The mean score for Week 4 was subtracted from the mean baseline score to obtain the mean change from baseline on the Global Improvement Score.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (36)
Genova Clinical Research
🇺🇸Tucson, Arizona, United States
Arkansas Gastroenterology
🇺🇸Sherwood, Arkansas, United States
Advanced Clinical Research Institute
🇺🇸Anaheim, California, United States
Edinger Medical Group Clinical Research Center
🇺🇸Fountain Valley, California, United States
Impact Clinical Trials
🇺🇸Los Angeles, California, United States
Community Clinical Trials
🇺🇸Orange, California, United States
AGMG - Orange
🇺🇸Orange, California, United States
Medical Associates Research Group
🇺🇸San Diego, California, United States
Lynn Instiute of the Rockies
🇺🇸Colorado Springs, Colorado, United States
Clinical Trials Management of Boca Raton, Inc.
🇺🇸Boca Raton, Florida, United States
Scroll for more (26 remaining)Genova Clinical Research🇺🇸Tucson, Arizona, United States